76 -6 (80) 2025 - Yusupova Sh.K., Chartakov A.K. - PREDIABETES: RENAL - METABOLIC RISK CONTINUUM

PREDIABETES: RENAL - METABOLIC RISK CONTINUUM

Yusupova Sh.K. - Andijan State Medical Institute

Chartakov A.K. - Andijan State Medical Institute

Resume

The aim of this study is to investigate renal dysfunction among patients with prediabetes. The study included 55 people aged 18 to 65 years, including 35 men (with an average age of 54.3 ± 3.2 years) and 20 women (with an average age of 51.1 ± 2.1 years), who were examined at the Andijan Regional Endocrinology Dispensary. The control group consisted of 20 healthy volunteers. The research methods included general clinical and biochemical tests, hormonal studies, instrumental methods (ECG, ultrasound, radiography, etc.). The results showed that prediabetes is a significant risk factor for the development of atherosclerosis, chronic kidney disease and heart failure. The risks increase with hemoglobin A1c levels above certain thresholds. The findings highlight the importance of developing strategies to reduce the risk of cardiovascular events in individuals with prediabetes, especially given the diversity of the glycemic spectrum. The findings may serve as a basis for improving clinical practice and developing early prevention measures in high-risk patients.

Keywords: prediabetes, renal risk, screening

First page

351

Last page

354

For citation:Yusupova Sh.K., Chartakov A.K. - PREDIABETES: RENAL - METABOLIC RISK CONTINUUM//New Day in Medicine 6(80)2025 351-354 https://newdayworldmedicine.com/en/new_day_medicine/6-80-2025

List of References

  1. Vart P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016 //JAMA network open. – 2020. – Т. 3. – №. 7. – С. e207932-e207932.
  2. Plantinga L. C. et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes //Clinical Journal of the American Society of Nephrology. – 2010. – Т. 5. – №. 4. – С. 673-682.
  3. Kidney G. Disease: Improving Global Outcomes Diabetes Work,“KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease” //Kidney Int. – 2022. – Т. 102. – С. S1-S127.
  4. American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes—2021 //Diabetes Care. – 2021. – Т. 44. – №. Supplement_1. – С. S85-S99.
  5. Sallar A., Dagogo-Jack S. Regression from prediabetes to normal glucose regulation: state of the science //Experimental Biology and Medicine. – 2020. – Т. 245. – №. 10. – С. 889-896.
  6. Kalaitzidis R. G., Bakris G. L. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? //Current opinion in nephrology and hypertension. – 2009. – Т. 18. – №. 5. – С. 386-391.
  7. Kim H. J. et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry //The Korean Journal of Internal Medicine. – 2021. – Т. 36. – №. 5. – С. 1102.
  8. Honigberg MC, Zekavat SM, Pirruccello JP, Natarajan P, Vaduganathan M. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. J Am Coll Cardiol. 2021 Aug 3;78(5):453-464. doi: 10.1016/j.jacc.2021.05.004.

    file

    download